{"id":"azt-3tc-idv-rtv","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL178240","moleculeType":"Small molecule","molecularWeight":"267.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZT and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs) that block the enzyme responsible for converting HIV RNA into DNA. IDV and RTV are protease inhibitors that prevent the cleavage of viral polyproteins, blocking the maturation of infectious viral particles. Together, this quadruple therapy targets two critical steps in the HIV replication cycle.","oneSentence":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:26.073Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00001083","phase":"PHASE2","title":"Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":240},{"nctId":"NCT00000874","phase":"","title":"A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1997-08","conditions":"HIV Infections","enrollment":148},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":"HIV-Associated Lipodystrophy Syndrome, Cardiovascular Disease","enrollment":80},{"nctId":"NCT00001119","phase":"NA","title":"Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-10","conditions":"HIV Infections","enrollment":288},{"nctId":"NCT00385957","phase":"PHASE4","title":"Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"","conditions":"HIV Infections","enrollment":70},{"nctId":"NCT00158405","phase":"PHASE3","title":"Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-12","conditions":"HIV Infections","enrollment":840},{"nctId":"NCT00433056","phase":"PHASE3","title":"Long Term Treatment Interruptions","status":"COMPLETED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2004-01","conditions":"HIV Infections, AIDS","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"AZT+3TC+IDV+RTV","genericName":"AZT+3TC+IDV+RTV","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination antiretroviral regimen inhibits HIV replication by blocking reverse transcriptase and protease enzymes simultaneously. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}